Get the Stockscreener App
7.63
5.24%
0.38
After Hours:
7.63
Upstream Bio Inc stock is traded at $7.63, with a volume of 666.43K.
It is up +5.24% in the last 24 hours and down -18.83% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$7.25
Open:
$7.52
24h Volume:
666.43K
Relative Volume:
0.94
Market Cap:
$415.22M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-2.6293
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-7.63%
1M Performance:
-18.83%
6M Performance:
-71.71%
1Y Performance:
-29.61%
1-Day Range:
$7.40
$7.86
1-Week Range:
$7.185
$8.64
52-Week Range:
$7.185
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.63 | 394.54M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
428.34 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.95 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.58 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.99 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio schedules fireside chat at global healthcare event - Traders Union
H.C. Wainwright Initiates UpStream Bio(UPB.US) With Buy Rating, Announces Target Price $36 - Moomoo
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
H.C. Wainwright initiates Upstream Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
UPB Price Today: Upstream Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio (UPB) Edges Higher Amid Quiet Trading, Holds Above Key SupportSupply Zone - thelegaladvocate.com
Upstream Bio Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Surprise Score - thelegaladvocate.com
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrowed Loss Per Share as Clinical Pipeline AdvancesEPS Growth Rate - thelegaladvocate.com
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target - TipRanks
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - Sahm
Upstream Bio (UPB) Reveals Promising Phase 2 Trial Results for V - GuruFocus
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026 - Traders Union
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma - Quiver Quantitative
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial - GlobeNewswire
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio (UPB) Surges +3.41%, Nearing $9.54 Resistance 2026-05-17Market Analysis - newser.com
MSN Money - MSN
Truist Financial Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB) - The Globe and Mail
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB) - The Globe and Mail
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $42 to $43 - Moomoo
Mizuho lowers Upstream Bio stock price target on operating spend tweaks - Investing.com Canada
Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating - Moomoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Sahm
Upstream Bio, Inc. 2026 Q1 Financials and Risk Factors – Nasdaq Global Select Market Filing - Minichart
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026) - marketscreener.com
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases - TradingView
Upstream Bio Reports Q1 2026 Results and Advances Verekitug Toward Phase 3 Trials for Severe Asthma, CRSwNP, and COPD - Minichart
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary - TradingView
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M - TradingView
Upstream Bio, Inc. (UPB) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
Upstream Bio, Inc. $UPB Shares Bought by UBS Group AG - MarketBeat
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA - MarketBeat
Upstream Bio Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
Should I buy Upstream Bio, Inc. (UPB) - Zacks Investment Research
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):